title: Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.
abstract: OBJECTIVE
  To prospectively evaluate in a multicenter randomized trial the antitumor activity of CD8(+) tumor-infiltrating lymphocytes (TILs) in combination with low-dose recombinant interleukin-2 (rIL-2), compared with rIL-2 alone, after radical nephrectomy in metastatic renal cell carcinoma patients.
  
  
  METHODS
  Between December 1994 and March 1997, 178 patients with resectable primary tumors were enrolled at 29 centers in the United States and Europe. Patients underwent total nephrectomy, recovered, and were randomized to receive either CD8(+) TILs (5 x 10(7) to 3 x 10(10) cells intravenously, day 1) plus rIL-2 (one to four cycles: 5 x 10(6) IU/m(2) by continuous infusion daily for 4 days per week for 4 weeks) (TIL/rIL-2 group) or placebo cell infusion plus rIL-2 (identical regimen) (rIL-2 control group). Primary tumor specimens were cultured at a central cell-processing center in serum-free medium containing rIL-2 to generate TILs.
  
  
  RESULTS
  Of 178 enrolled patients, 160 were randomized (TIL/rIL-2 group, n = 81; rIL-2 control group, n = 79). Twenty randomized patients received no treatment after nephrectomy because of surgical complications (four patients), operative mortality (two patients), or ineligibility for rIL-2 therapy (14 patients). Among 72 patients eligible for TIL/rIL-2 therapy, 33 (41%) received no TIL therapy because of an insufficient number of viable cells. Intent-to-treat analysis demonstrated objective response rates of 9.9% v 11.4% and 1-year survival rates of 55% v 47% in the TIL/rIL-2 and rIL-2 control groups, respectively. The study was terminated early for lack of efficacy as determined by the Data Safety Monitoring Board.
  
  
  CONCLUSIONS
  Treatment with CD8(+) TILs did not improve response rate or survival in patients treated with low-dose rIL-2 after nephrectomy.
authors.affiliation: University of California, Los Angeles, Los Angeles, CA, USA. rfiglin@med1.medsch.ucla.edu
authors.forename: R A
authors.initials: RA
authors.lastname: Figlin
authors.forename: J A
authors.initials: JA
authors.lastname: Thompson
authors.forename: R M
authors.initials: RM
authors.lastname: Bukowski
authors.forename: N J
authors.initials: NJ
authors.lastname: Vogelzang
authors.forename: A C
authors.initials: AC
authors.lastname: Novick
authors.forename: P
authors.initials: P
authors.lastname: Lange
authors.forename: G D
authors.initials: GD
authors.lastname: Steinberg
authors.forename: A S
authors.initials: AS
authors.lastname: Belldegrun
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D011994:Recombinant Proteins; D016019:Survival Analysis
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins